Clear Street downgraded Akero Therapeutics (AKRO) to Hold from Buy with a price target of $54, up from $49, following Novo Nordisk’s (NVO) plan to acquire Akero for $4.7B upfront, equivalent to about $54 per share.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO: